cris.boxmetadata.label.title
Inflammatory mechanisms and oxidative stress as key factors responsible for progression of neurodegeneration: Role of brain innate immune system
cris.boxmetadata.label.dateissued
01 browse.startsWith.months.april 2016
cris.boxmetadata.label.accesslevel
metadata only access
cris.boxmetadata.label.resourcetype
journal article
cris.boxmetadata.label.authors
Pontificia Universidad Javeriana
cris.boxmetadata.label.publisher
Bentham Science Publishers B.V.
cris.boxmetadata.label.abstract
Chronic inflammation is characterized by longstanding microglial activation followed by sustained release of inflammatory mediators, which aid in enhanced nitrosative and oxidative stress. The sustained release of inflammatory mediators propels the inflammatory cycle by increased microglial activation, promoting their proliferation and thus stimulating enhanced release of inflammatory factors. Elevated levels of several cytokines and chronic neuroinflammation have been associated with many neurodegenerative disorders of central nervous system like age-related macular degeneration, Alzheimer disease, multiple sclerosis, Parkinson’s disease, Huntington’ disease, and tauopathies. This review highlights the basic mechanisms of neuroinflammation, the characteristics of neurodegenerative diseases, and the main immunologic responses in CNS neurodegenerative disorders. A comprehensive outline for the crucial role of microglia in neuroinflammation and neurodegeneration and the role of Toll-like receptor signalling in coexistence of inflammatory mechanisms and oxidative stress as major factors responsible for progression of neurodegeneration have also been presented.
cris.boxmetadata.label.citationstartpage
329
cris.boxmetadata.label.citationendpage
336
cris.boxmetadata.label.volume
15
cris.boxmetadata.label.issue
3
cris.boxmetadata.label.language
English
cris.boxmetadata.label.ocdeknowledgeArea
Neurociencias
Inmunología
cris.boxmetadata.label.doi
cris.boxmetadata.label.scopusidentifier
2-s2.0-84961577153
cris.boxmetadata.label.pubmedidentifier
cris.boxmetadata.label.source
CNS and Neurological Disorders - Drug Targets
cris.boxmetadata.label.containerissn
18715273
cris.boxmetadata.label.sponsor
This study was supported by the GALLY International Biomedical Research Consulting LLC, San Antonio, Texas, USA, and Russian Science Foundation (RSCF: ? 14-23-00160). GEB work is supported by Pontificia Universidad Javeriana and Universidad Autonoma de Chile.
peru-layout.shadow-copies
Directorio de Producción Científica
Scopus